New structural classes of antimalarials

Eur J Med Chem. 2022 Nov 15:242:114653. doi: 10.1016/j.ejmech.2022.114653. Epub 2022 Aug 10.

Abstract

Malaria remains a major vector borne disease claiming millions of lives worldwide due to infections caused by Plasmodium sp. Discovery and development of antimalarial drugs have previously been dominated majorly by single drug therapy. The malaria parasite has developed resistance against first line and second line antimalarial drugs used in the single drug therapy. This has drawn attention to find ways to alleviate the disease burden supplanted by combination therapy with multiple drugs to overcome drug resistance. Emergence of resistant strains even against the combination therapy has now mandated the revision of the current antimalarial pharmacotherapy. Research efforts of the past decade led to the discovery and identification of several new structural classes of antimalarial agents with improved biological attributes over the older ones. The following is a comprehensive review, addressed to the new structural classes of heterocyclic and natural compounds that have been identified during the last decade as antimalarial agents. Some of the classes included herein contain one or more pharmacophores amalgamated into a single bioactive scaffold as antimalarial agents, which act upon the conventional and novel targets.

Keywords: Drug resistant strains; Heterocyclic compounds; Malaria; Natural products; Plasmodium sp..

Publication types

  • Review

MeSH terms

  • Antimalarials* / chemistry
  • Drug Resistance
  • Humans
  • Malaria* / drug therapy
  • Plasmodium falciparum
  • Plasmodium*

Substances

  • Antimalarials